Compare iShares Core High Dividend ETF (HDV) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Medpace Holdings Inc — how do they compare? iShares Core High Dividend ETF trades at $28.77 (market cap $14.68B), while Medpace Holdings Inc trades at $613.05 (market cap $16.82B). The key difference: iShares Core High Dividend ETF and Medpace Holdings Inc are close in size by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares Core High Dividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Medpace Holdings Inc for 14 Days on average.
| HDV | MEDP | |
|---|---|---|
Market Cap | $14.68B | $16.82B |
Volume | 2,925,562 | 223,093 |
52-Week High | $29.93 | $630.19 |
52-Week Low | $23.64 | $393.42 |
Typical Hold Time | 117 Days | 14 Days |
Sector | — | Health |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.73, up 1.59% with strong bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation, though the 3% yield may not fully compensate for increased concentration risk.
The outlook remains cautiously optimistic given the bullish technical setup and sector rotation benefits, but investors face risks from heightened concentration in three sectors (62% allocation) and potential yield compression. The ETF's performance relative to peers like VYM suggests competitive positioning, though sector concentration requires monitoring for diversification adequacy.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
